Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
NCT06015893 Semaglutide Therapy for Alcohol Reduction (STAR) Status: Recruiting This study will test the safety/tolerability and early efficacy of subcutaneous (s.c.) semaglutide at the dose of 2.4 mg/week or maximum tolerated dose (MTD) as a potential new treatment for alcohol use disorder (AUD)
The PEC voted unanimously on Tuesday to let the city change its Blue Cross Blue Shield of Massachusetts health care plan to implement utilization management, requiring doctors to get approval from employees insurance providers before prescribing certain medications
An AI solution may be implemented to identify and predict current and future patients, improve clinical outcomes, or enhance transparency/predictability within the patient journey
evidence gaps
US$ 29.20
US$ 21.81
US$ 24.75
